BE features a broad range of promising projects in various stages of development. Some of which are highlighted below:
VACCINES IN PIPELINE
Liquid Hexavalent Vaccine : In 2013, GlaxoSmithKline and Biological E partnered to develop liquid hexavalent vaccine. The vaccine comprises of diphtheria, tetanus, whole cell pertussis, inactivated polio, haemophilus influenzae type B and hepatitis B.
Pneumococcal Conjugate Vaccine : Biological E is developing a pneumococcal conjugate vaccine comprising of 13 pneumo serotypes.
Typhoid Conjugate Vaccine : Biological E entered into a technology transfer arrangement with Novartis Vaccine Institute for Global Health (NVGH) in 2013. NVGH had completed Phase 2 trial prior to the technology transfer.
Paratyphoid Vaccine : In addition to the typhoid conjugate vaccine, Novartis Vaccine Institute for Global Health (NVGH) has licensed paratyphoid vaccine technology to Biological E.
Measles Rubella Vaccine : Biological E is developing a measles rubella vaccine. In 2013, Biological E received a commercial grant for this vaccine from Bill and Melinda Gates Foundation.
Inactivated Polio Vaccine : Biological E and Statens Serum Institut (SSI) entered into a technology transfer arrangement for inactivated polio vaccine in 2013 and technology transfer was started immediately. Currently in-house process improvement is being done at Nantes, France.
Inactivated Rotavirus Vaccine : Biological E licensed the technology from Centre for Disease Control and Prevention (CDC) in 2012 and the vaccine is being developed at the company’s facility in Nantes.
Meningitis Vaccine : In 2014, Biological E has started research in order to develop a Men ACWY vaccine.
Biological E respects intellectual property owned by others. Products that are under patent protection in India, are intended for the purpose of Research & Development and for generating data for regulatory submissions.